Ventolin Hfa is a drug owned by Glaxosmithkline Intellectual Property Ltd England. It is protected by 35 US drug patents filed from 2013 to 2018. Out of these, 2 drug patents are active and 33 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 04, 2025. Details of Ventolin Hfa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7500444 (Pediatric) | Actuation indicator for a dispensing device |
Jul, 2025
(6 months from now) | Active |
| US7500444 | Actuation indicator for a dispensing device |
Jan, 2025
(16 days from now) | Active |
|
US7832351 (Pediatric) | Actuation indicator for a dispensing device |
Dec, 2023
(a year ago) |
Expired
|
| US7832351 | Actuation indicator for a dispensing device |
Jun, 2023
(1 year, 6 months ago) |
Expired
|
|
US6743413 (Pediatric) | Suspension aerosol formulations |
Dec, 2021
(3 years ago) |
Expired
|
| US6743413 | Suspension aerosol formulations |
Jun, 2021
(3 years ago) |
Expired
|
| US9861771 | Device housing for an aerosol container |
Oct, 2020
(4 years ago) |
Expired
|
|
US7350676 (Pediatric) | Valve for aerosol container |
Feb, 2019
(5 years ago) |
Expired
|
|
US6431168 (Pediatric) | Dispenser with doses′ counter |
Dec, 2018
(6 years ago) |
Expired
|
|
US7107986 (Pediatric) | Dispenser with doses' counter |
Dec, 2018
(6 years ago) |
Expired
|
| US7350676 | Valve for aerosol container |
Aug, 2018
(6 years ago) |
Expired
|
|
US7143908 (Pediatric) | Indicating device |
Jul, 2018
(6 years ago) |
Expired
|
|
US6161724 (Pediatric) | Indicating device |
Jul, 2018
(6 years ago) |
Expired
|
|
US6435372 (Pediatric) | Delivery system for a medicament and method for the assembly thereof |
Jul, 2018
(6 years ago) |
Expired
|
|
US6938796 (Pediatric) | Indicating device |
Jul, 2018
(6 years ago) |
Expired
|
|
US6997349 (Pediatric) | Indicating device |
Jul, 2018
(6 years ago) |
Expired
|
|
US6315173 (Pediatric) | Valve for aerosol container |
Jun, 2018
(6 years ago) |
Expired
|
|
US6966467 (Pediatric) | Valve for aerosol container |
Jun, 2018
(6 years ago) |
Expired
|
|
US6510969 (Pediatric) | Valve for aerosol container |
Jun, 2018
(6 years ago) |
Expired
|
|
US6170717 (Pediatric) | Valve for aerosol container |
Jun, 2018
(6 years ago) |
Expired
|
| US6431168 | Dispenser with doses′ counter |
Jun, 2018
(6 years ago) |
Expired
|
| US7107986 | Dispenser with doses' counter |
Jun, 2018
(6 years ago) |
Expired
|
| US6938796 | Indicating device |
Jan, 2018
(6 years ago) |
Expired
|
| US6997349 | Indicating device |
Jan, 2018
(6 years ago) |
Expired
|
| US7143908 | Indicating device |
Jan, 2018
(6 years ago) |
Expired
|
| US6161724 | Indicating device |
Jan, 2018
(6 years ago) |
Expired
|
| US6435372 | Delivery system for a medicament and method for the assembly thereof |
Jan, 2018
(6 years ago) |
Expired
|
| US6315173 | Valve for aerosol container |
Dec, 2017
(6 years ago) |
Expired
|
| US6510969 | Valve for aerosol container |
Dec, 2017
(6 years ago) |
Expired
|
| US6170717 | Valve for aerosol container |
Dec, 2017
(6 years ago) |
Expired
|
| US6966467 | Valve for aerosol container |
Dec, 2017
(6 years ago) |
Expired
|
|
US6558651 (Pediatric) | Aerosols containing annealed particulate salbutamol and tetrafluoroethane |
Jun, 2017
(7 years ago) |
Expired
|
| US6558651 | Aerosols containing annealed particulate salbutamol and tetrafluoroethane |
Dec, 2016
(8 years ago) |
Expired
|
|
US6596260 (Pediatric) | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
Feb, 2015
(9 years ago) |
Expired
|
| US6596260 | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
Aug, 2014
(10 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Ventolin Hfa and ongoing litigations to help you estimate the early arrival of Ventolin Hfa generic.
Ventolin Hfa's Litigations
Ventolin Hfa been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 26, 2001, against patent number US6596260. The petitioner , challenged the validity of this patent, with BRUGGER et al as the respondent. Click below to track the latest information on how companies are challenging Ventolin Hfa's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6743413 | September, 2015 |
Terminated-Settled
(18 Nov, 2016) | 3M Company | Mylan Pharmaceuticals Inc. |
| US6596260 | July, 2001 |
Decision
(25 Sep, 2002) | BRUGGER et al | |
US patents provide insights into the exclusivity only within the United States, but Ventolin Hfa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ventolin Hfa's family patents as well as insights into ongoing legal events on those patents.
Ventolin Hfa's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ventolin Hfa's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 04, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ventolin Hfa Generic API suppliers:
Albuterol Sulfate is the generic name for the brand Ventolin Hfa. 46 different companies have already filed for the generic of Ventolin Hfa, with Teva having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ventolin Hfa's generic
Alternative Brands for Ventolin Hfa
Ventolin Hfa which is used for managing bronchospasm in adults and children with reversible obstructive airways disease and preventing exercise-induced bronchospasm in patients 4 years and older., has several other brand drugs using the same active ingredient (Albuterol Sulfate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Astrazeneca |
| |||
| Boehringer Ingelheim |
| |||
| Kindeva |
| |||
| Norvium Bioscience |
| |||
| Teva Branded Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Albuterol Sulfate, Ventolin Hfa's active ingredient. Check the complete list of approved generic manufacturers for Ventolin Hfa
About Ventolin Hfa
Ventolin Hfa is a drug owned by Glaxosmithkline Intellectual Property Ltd England. It is used for managing bronchospasm in adults and children with reversible obstructive airways disease and preventing exercise-induced bronchospasm in patients 4 years and older. Ventolin Hfa uses Albuterol Sulfate as an active ingredient. Ventolin Hfa was launched by Glaxosmithkline in 2001.
Approval Date:
Ventolin Hfa was approved by FDA for market use on 19 April, 2001.
Active Ingredient:
Ventolin Hfa uses Albuterol Sulfate as the active ingredient. Check out other Drugs and Companies using Albuterol Sulfate ingredient
Treatment:
Ventolin Hfa is used for managing bronchospasm in adults and children with reversible obstructive airways disease and preventing exercise-induced bronchospasm in patients 4 years and older.
Dosage:
Ventolin Hfa is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.09MG BASE/INH | AEROSOL, METERED | Prescription | INHALATION |